A study published in Nature Medicine has uncovered biomarkers that could help select the most effective precision treatments for patients with late-stage prostate cancer. Led by Vancouver Coastal Health Research Institute researcher Dr. Alexander Wyatt, a key advantage of the approach is that it can be performed using a simple blood test.
“Ultimately, this work helps move us closer to true precision oncology — matching the right treatment to the right patient at the right time,” states Wyatt.
